UBC, Université de Sherbrooke, and Cornell University researchers report a new enzyme-blocking compound delivered in a nasal spray that effectively treats delta variant infection in mice. Human trials dependent on securing funding.

Dr. Barry Dworkin

Medical Mythbusting Commentary for March 29, 2022

[display_podcast]

Source:
New compound delivered in a nasal spray effectively treats delta variant infection in mice

Reference:
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic

Related posts:

  1. Unpublished, uncontrolled small study claims that experimental exosome treatment shortens recovery time to five days for patients with severe Covid-19. Further human trials required to prove it truly works.
  2. First step studying the outcomes of a one-and-done therapy using pegylated interferon lambda demonstrated that it helped curb severe COVID-19 infection-related hospitalizations.
  3. Study shows ten percent of people, mostly men, with severe COVID-19, develop an autoimmune response that attacks interferons (part of the immune system) thereby reducing the host’s ability to defend against the virus.
  4. Researchers start the trek to figure out the biological mechanism how COVID infections lead to autoimmune disease even after recovery. First clues found that may lead to understanding Long-COVID. More to come. #GoScience #VaccinesWork